What is the pathway to patient-centric ethical drug development?

Pathway to patient-centric drug development

Shift from patient engagement to public engagement

Healthcare in Japan is transitioning from care that patients passively receive, to one that they independently choose.
This trend is becoming increasingly important, not only in terms of patients’ conducting their own research and openly discussing information with healthcare professionals, but also within drug research and development. Why is collaboration between pharmaceutical researchers and patients or citizens, which was minimal in the past, needed more now? How can this be achieved?
To answer this question and more, we interviewed Dr. Imamura, who is taking on the challenge of creating a place where researchers and patients can learn together.

MatsubaraWhat is the pathway to patient-centric ethical drug development?
Read More

Cosmo PR and HekaBio Announce Strategic Partnership and Investment in HekaBio

Cosmo PR and HekaBio Announce Strategic Partnership and Investment in HekaBio


HekaBio K.K. (hereafter: HekaBio) and Cosmo Public Relations Corporation (hereafter: Cosmo) have announced that Cosmo has made an investment in HekaBio and that the companies have entered into a strategic partnership to increase awareness of and accessibility to emerging innovations in the bioscience field that will aid in meeting the needs of patients and society as a whole.


“I am delighted with Cosmo’s investment and the strategic partnership, which I believe will be highly synergistic as we develop and bring to market a broad range of MedTech and pharma innovations that are needed in Japan. In Cosmo’s Healthcare group (hereafter “Cosmo Healthcare”), we have a strong partner with shared values. Our partnership will enable us to make a greater contribution to society through our collaborative business activities. HekaBio specializes in early access to assets in development in worldwide biotech, regenerative medicine and MedTech ventures, and the success of these programs will be greatly enhanced through collaborations that can be forged in Cosmo Healthcare’s established network” said Rob Claar, CEO of HekaBio.


“Cosmo Healthcare is constantly looking for a way to broaden knowledge of cutting-edge innovations that will lead to healthcare advancements in Japan. HekaBio has such innovative programs that there is no overlap with the activities of any of our current clients. We look forward to working with HekaBio to introduce innovative ideas and create opportunities for the further development of pharmaceuticals, delivery systems and devices that can fulfill the needs of patients and help create a healthier society” said Kumi Sato, President and CEO of Cosmo.


About HekaBio K.K.
HekaBio is an ecosystem for accelerating healthcare innovations in Japan, operating as an in-licensing bio venture, a business development firm and a contract research organization (CRO). HekaBio focuses on solutions with high potential to address patients’ unmet medical needs and deliver cost savings for society. HekaBio currently has nearly 50 programs under management, many of which are new category innovations highly valued among Japanese clinicians.


About Cosmo Public Relations Corporation
Cosmo is a long-established leader in developing communications strategies across a broad range of life science specialties. It has a firm understanding of the Japanese healthcare regulatory framework, a wide network of experts across the entire healthcare sector and unrivaled contacts within the Japanese media. Its skills in qualitative and quantitative analyses make it adept at reading public sentiment and understanding the innovations of a broad range of healthcare professionals, thereby making it able to improve communication and match interests among different stakeholders.


Press Contact:

HekaBio K.K.
Mari Tanaka

COSMO HEALTHCARE, Cosmo Public Relations Corporation
Yoko Awata

Tomomi-NagasawaCosmo PR and HekaBio Announce Strategic Partnership and Investment in HekaBio
Read More

Online Survey of 300 Cancer Patients in Japan

Online Survey of 300 Cancer Patients in Japan

Real Patient Experiences of Choosing Cancer Treatment Revealed

30% Followed Doctors’ Recommendation Without Sufficient Understanding


TOKYO – July 31, 2020 – In light of the growing number of cancer treatment options now available, COSMO HEALTHCARE has conducted a nationwide online survey of 300 patients across ten major types of cancer in order to gain insight into how informed cancer patients are when deciding on treatment options.

MatsubaraOnline Survey of 300 Cancer Patients in Japan
Read More

COSMO Healthcare Interview: “Japan in 10 Minutes”

No. 2: Dr. Masaharu Tsubokura, MD, of Hirata Central Hospital in Fukushima

As the second segment of COSMO’s “Japan in 10 Minutes” interview series, our CEO Kumi Sato interviews with Dr. Tsubokura, of Hirata Central Hospital in Japan.
In the interview, Dr. Tsubokura discussed the situation about PCR testing and Antibody testing in Japan.

Tomomi-NagasawaCOSMO Healthcare Interview: “Japan in 10 Minutes”
Read More

Corporate Relevance:Communications Strategies in the COVID-19 Age

1. Should we expect a paradigm shift?

Finally we are seeing a flattening of the worldwide COVID-19 curve and lifting of lockdowns across major cities. On May 14, Japan lifted its state of emergency for 39 prefectures. With people and businesses asked to either refrain entirely or severely restrict so many activities during the crisis, we are now entering a new phase of resuming daily life while coexisting with the virus.

Some experts are predicting that the post-COVID-19 world will be accompanied by a transformational paradigm shift, spanning every aspect of our lives from business and commerce, to education to politics. Indeed, the pandemic has already ushered in rapid adoption of long-advocated initiatives, such as cashless society, online shopping, teleworking, paperless society, online education, and telemedicine. We can now finally predict that Japan will see step changes in these areas, with COVID-19 acting as the catalyst.


Tomomi-NagasawaCorporate Relevance:Communications Strategies in the COVID-19 Age
Read More

COVID-19: Countering the Impact and Navigating Your PR Response

– Disclosing Sensitive Information and Planning Media Events –

The global spread of COVID-19 is showing no signs of abating. Companies are faced with the challenge of taking sufficient measures to prevent transmission and minimize impact, while simultaneously sustaining their business. In these circumstances, how should those of us in the field of public relations respond?

In today’s newsletter, we will apply some of the basic tenets of public relations to this unique situation and focus on two key areas with practical tips. Firstly, how to disclose sensitive information if an employee becomes infected and secondly, the critical decisions that must be taken when considering whether to go ahead with a press conference or media event in Japan.

Tomomi-NagasawaCOVID-19: Countering the Impact and Navigating Your PR Response
Read More

COSMO Holds Reputation Risk Management Seminar

COSMO held the seminar, “Proactive Reputation Risk Management,” on November 15 spotlighting its renewed “Reputation Risk Management” core offerings.

As the pharmaceutical and medical device industries grow increasingly complex, demand for reputation risk management also increases. Even risk-averse companies have inevitably faced incidents.

Instead of approaching communication as an add-on service, COSMO recommends proactive reputation risk management, which involves strategic actions based on two cornerstones: The first cornerstone is to upgrade “risk intelligence.” It is important to take a data-driven approach to quantify reputation, including potential risks, on a regular basis. Visualizing specifics and how to fill which gaps illuminates clear strategic directions and enables planning of concrete actions.

The second cornerstone is improving the “risk management” process. This involves proactively identifying risks and bolstering resilience. A bird’s eye view of the whole process is needed to ascertain internal alignment of risk awareness, clarity of governance, and team responsibilities, and training standards.

ObaCOSMO Holds Reputation Risk Management Seminar
Read More

Optimism for 2020

We’re now a month into 2020, but this year is a significant milestone for COSMO, marking the 60th anniversary of our agency. Since our establishment in 1960, COSMO has evolved from providing editorial services for Japanese companies to being a pioneer in Japan’s communications industry, now specializing in globally-focused healthcare consultancy. A key driving force for COSMO’s business growth has always been to strive to make progress in our field. During this landmark year, we will continue to make advancements in healthcare communications that deliver meaningful value for our clients.

ObaOptimism for 2020
Read More

EyeforPharma Patient Summit USA: Patient Engagement Insights

Q&A with the Change Makers at the Forefront of Patient-Centricity

COSMO’s senior consultant in Washington DC, Emi Yasukawa, reports on the EyeforPharma Patient Summit USA held October 2 – 3. At the two-day summit in Philadelphia, pharmaceutical industry professionals and patient advocacy groups gathered to share their insights move the industry forward.

In this article, I am honored to share insights and takeaways from three change makers. The following are three key takeaways that will help us form our next moves regarding patient engagement:

  1. The industry is shifting from working for patients, to working with patients.
    Many patient groups voiced concerns that research conducted without their direct involvement was incongruent with patient needs. Involving patients throughout the development process will give profound insights into how the disease is understood. John Linnell, a COPD patient and director of the US COPD Coalition, aptly summed this up, “If it is without us [patients], it is not about us.”
    Read John’s interview on his involvement as a COPD patient »

  2. There is synergy between patient and employee engagement.
    EyeforPharma polled the audience about their beliefs about where patient centricity begins; 70% of attendees responded that patient centricity begins from a top down and then bottom-up approach.
    Dr. Lode Dewulf, Chief Patient Affairs Officer of Servier Group, says that it is important not to create a standardized approach to internally organize for patient engagement, noting that the first step is to understand the very specific needs and aspirations of the company.
    Read Dr. Dewulf’s perspectives as Chief Patient Officer »

  3. Patient engagement involves more than patients; it involves their families, patient groups, healthcare professionals, caretakers and the community.
    Kazuyoshi Hatanaka, Chairman of Japan Partners for Patient-Centric Care (JPPaC), strives to improve pharmaceuticals for patients. Historically, patients were seen as consumers of pharmaceuticals; however, Mr. Hatanaka’s NPO is expanding the circle of patient centricity in Japan and bridging dialogue between patients, patient advocacy groups, pharmaceutical companies, and HCPs.
    Read Mr. Hatanaka’s insights on patient engagement in Japan »
ObaEyeforPharma Patient Summit USA: Patient Engagement Insights
Read More